Giffin Brett A. 4/A
4/A · T2 Biosystems, Inc. · Filed Nov 28, 2023
Insider Transaction Report
Form 4/AAmended
Giffin Brett A.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-02-20$0.65/sh−537$349→ 3,049 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−1,333→ 2,667 total→ Common Stock (1,333 underlying) - Exercise/Conversion
Common Stock
2023-02-20+1,333→ 3,586 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The original Form 4 filed on March 9, 2023 is amended by this Form 4 amendment to correct the amount of securities beneficially owned following the reported transactions.
- [F3]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on November 10, 2021.
- [F4]On February 20, 2022 the reporting person was granted 4,000 RSU's that vest in three equal annual installments commencing on February 20, 2023.